O	0	1	[	[	(	O
O	1	2	A	A	DT	B-NP
O	3	7	case	case	NN	I-NP
O	8	14	report	report	NN	I-NP
O	15	17	of	of	IN	B-PP
O	18	26	advanced	advance	VBN	B-NP
B-Cancer	27	34	gastric	gastric	JJ	I-NP
I-Cancer	35	41	cancer	cancer	NN	I-NP
O	42	52	responding	respond	VBG	B-VP
O	53	55	to	to	TO	B-PP
O	56	58	TS	TS	NN	B-NP
O	58	59	-	-	HYPH	B-NP
O	59	60	1	1	CD	I-NP
O	60	61	,	,	,	O
O	62	63	a	a	DT	B-NP
O	64	69	novel	novel	JJ	I-NP
B-Organism_subdivision	70	74	oral	oral	JJ	I-NP
O	75	87	fluorouracil	fluorouracil	NN	I-NP
O	88	98	derivative	derivative	NN	I-NP
O	98	99	]	]	)	O
O	99	100	.	.	.	O

O	102	104	TS	TS	NN	B-NP
O	104	105	-	-	HYPH	B-NP
O	105	106	1	1	CD	I-NP
O	107	109	is	be	VBZ	B-VP
O	110	111	a	a	DT	B-NP
O	112	115	new	new	JJ	I-NP
O	115	116	,	,	,	I-NP
B-Organism_subdivision	117	121	oral	oral	JJ	I-NP
B-Cancer	122	132	anticancer	anticancer	JJ	I-NP
O	133	138	agent	agent	NN	I-NP
O	139	147	composed	compose	VBN	B-VP
O	148	150	of	of	IN	B-PP
O	151	154	two	two	CD	B-NP
O	155	165	modulators	modulator	NNS	I-NP
O	165	166	,	,	,	O
O	167	176	gimeracil	gimeracil	NN	B-NP
O	177	178	(	(	(	O
O	178	182	CDHP	CDHP	NN	B-NP
O	182	183	)	)	)	O
O	184	187	and	and	CC	O
O	188	196	oteracil	oteracil	NN	B-NP
O	197	206	potassium	potassium	NN	I-NP
O	207	208	(	(	(	O
O	208	211	Oxo	Oxo	NN	B-NP
O	211	212	)	)	)	O
O	213	216	are	be	VBP	B-VP
O	217	222	mixed	mix	VBN	B-ADJP
O	223	227	with	with	IN	B-PP
O	228	235	tegafur	tegafur	NN	B-NP
O	236	238	in	in	IN	B-PP
O	239	240	a	a	DT	B-NP
O	241	246	ratio	ratio	NN	I-NP
O	247	249	of	of	IN	B-PP
O	250	251	1	1	CD	B-NP
O	251	252	:	:	:	O
O	252	253	0	0	CD	B-NP
O	253	254	.	.	.	I-NP
O	254	255	4	4	CD	I-NP
O	255	256	:	:	:	O
O	256	257	1	1	CD	B-NP
O	257	258	.	.	.	O

O	259	261	We	We	PRP	B-NP
O	262	268	report	report	VBP	B-VP
O	269	272	one	one	CD	B-NP
O	273	277	case	case	NN	I-NP
O	278	280	of	of	IN	B-PP
O	281	289	advanced	advance	VBN	B-NP
B-Cancer	290	297	gastric	gastric	JJ	I-NP
I-Cancer	298	304	cancer	cancer	NN	I-NP
O	305	309	with	with	IN	B-PP
B-Cancer	310	314	lung	lung	NN	B-NP
O	315	318	and	and	CC	I-NP
B-Cancer	319	324	lymph	lymph	NN	I-NP
I-Cancer	325	329	node	node	NN	I-NP
I-Cancer	330	340	metastases	metastasis	NNS	I-NP
O	341	345	that	that	WDT	B-NP
O	346	356	completely	completely	RB	B-ADVP
O	357	366	responded	respond	VBD	B-VP
O	367	369	to	to	TO	B-PP
O	370	372	TS	TS	NN	B-NP
O	372	373	-	-	HYPH	B-NP
O	373	374	1	1	CD	I-NP
O	374	375	.	.	.	O

O	376	377	A	A	DT	B-NP
O	378	380	71	71	CD	I-NP
O	380	381	-	-	HYPH	I-NP
O	381	385	year	year	NN	I-NP
O	385	386	-	-	HYPH	O
O	386	389	old	old	JJ	B-NP
O	390	395	woman	woman	NN	I-NP
O	396	399	was	be	VBD	B-VP
O	400	408	admitted	admit	VBN	I-VP
O	409	411	to	to	TO	B-PP
O	412	415	our	our	PRP$	B-NP
O	416	424	hospital	hospital	NN	I-NP
O	425	432	because	because	IN	B-PP
O	433	435	of	of	IN	I-PP
O	436	450	breathlessness	breathlessness	NN	B-NP
O	450	451	.	.	.	O

O	452	453	A	A	DT	B-NP
O	454	463	diagnosis	diagnosis	NN	I-NP
O	464	466	of	of	IN	B-PP
O	467	475	advanced	advance	VBN	B-NP
B-Cancer	476	483	gastric	gastric	JJ	I-NP
I-Cancer	484	490	cancer	cancer	NN	I-NP
O	491	495	with	with	IN	B-PP
O	496	505	extensive	extensive	JJ	B-NP
B-Cancer	506	511	lymph	lymph	NN	I-NP
I-Cancer	512	516	node	node	NN	I-NP
I-Cancer	517	527	metastases	metastasis	NNS	I-NP
O	528	531	and	and	CC	O
O	532	540	multiple	multiple	JJ	B-NP
B-Cancer	541	550	pulmonary	pulmonary	JJ	I-NP
I-Cancer	551	561	metastases	metastasis	NNS	I-NP
O	562	565	was	be	VBD	B-VP
O	566	570	made	make	VBN	I-VP
O	570	571	.	.	.	O

O	572	575	One	One	CD	B-NP
O	576	583	hundred	hundred	CD	I-NP
O	584	586	mg	mg	NN	I-NP
O	586	587	/	/	SYM	B-NP
O	587	591	body	body	NN	I-NP
O	591	592	/	/	SYM	B-NP
O	592	595	day	day	NN	I-NP
O	596	598	of	of	IN	B-PP
O	599	601	TS	TS	NN	B-NP
O	601	602	-	-	HYPH	B-NP
O	602	603	1	1	CD	I-NP
O	604	607	was	be	VBD	B-VP
B-Organism_subdivision	608	614	orally	orally	RB	I-VP
O	615	628	administrated	administrate	VBN	I-VP
O	629	632	for	for	IN	B-PP
O	633	634	4	4	CD	B-NP
O	635	640	weeks	week	NNS	I-NP
O	640	641	.	.	.	O

O	642	643	A	A	DT	B-NP
O	644	651	partial	partial	JJ	I-NP
O	652	660	response	response	NN	I-NP
O	661	662	(	(	(	O
O	662	664	PR	PR	NN	B-NP
O	664	665	)	)	)	O
O	666	669	was	be	VBD	B-VP
O	670	678	obtained	obtain	VBN	I-VP
O	679	684	after	after	IN	B-PP
O	685	688	the	the	DT	B-NP
O	689	694	first	first	JJ	I-NP
O	695	701	course	course	NN	I-NP
O	702	706	with	with	IN	B-PP
O	707	717	regression	regression	NN	B-NP
O	718	720	of	of	IN	B-PP
O	721	729	multiple	multiple	JJ	B-NP
B-Cancer	730	739	pulmonary	pulmonary	JJ	I-NP
I-Cancer	740	750	metastases	metastasis	NNS	I-NP
O	750	751	.	.	.	O

O	752	757	After	After	IN	B-PP
O	758	759	1	1	CD	B-NP
O	760	764	drug	drug	NN	I-NP
O	764	765	-	-	HYPH	B-NP
O	765	769	free	free	JJ	I-NP
O	770	774	week	week	NN	I-NP
O	774	775	,	,	,	O
O	776	779	the	the	DT	B-NP
O	780	786	second	second	JJ	I-NP
O	787	793	course	course	NN	I-NP
O	794	797	was	be	VBD	B-VP
O	798	810	administered	administer	VBN	I-VP
O	811	815	with	with	IN	B-PP
O	816	819	120	120	CD	B-NP
O	820	822	mg	mg	NN	I-NP
O	822	823	/	/	SYM	B-NP
O	823	827	body	body	NN	I-NP
O	827	828	/	/	SYM	B-NP
O	828	831	day	day	NN	I-NP
O	832	834	of	of	IN	B-PP
O	835	837	TS	TS	NN	B-NP
O	837	838	-	-	HYPH	B-NP
O	838	839	1	1	CD	I-NP
O	840	843	for	for	IN	B-PP
O	844	845	4	4	CD	B-NP
O	846	851	weeks	week	NNS	I-NP
O	851	852	.	.	.	O

O	853	858	After	After	IN	B-PP
O	859	862	two	two	CD	B-NP
O	863	870	courses	course	NNS	I-NP
O	870	871	,	,	,	O
O	872	875	the	the	DT	B-NP
B-Cancer	876	883	primary	primary	JJ	I-NP
I-Cancer	884	889	tumor	tumor	NN	I-NP
O	890	893	was	be	VBD	B-VP
O	894	901	reduced	reduce	VBN	I-VP
O	902	904	to	to	TO	B-PP
O	905	907	an	an	DT	B-NP
B-Pathological_formation	908	913	ulcer	ulcer	NN	I-NP
I-Pathological_formation	914	918	scar	scar	NN	I-NP
O	919	923	with	with	IN	B-PP
O	924	936	pathological	pathological	JJ	B-NP
O	937	949	confirmation	confirmation	NN	I-NP
O	950	952	of	of	IN	B-PP
O	953	954	a	a	DT	B-NP
O	955	963	complete	complete	JJ	I-NP
O	964	977	disappearance	disappearance	NN	I-NP
O	978	980	of	of	IN	B-PP
O	981	984	the	the	DT	B-NP
B-Tissue	985	991	cancer	cancer	NN	I-NP
I-Tissue	992	998	tissue	tissue	NN	I-NP
O	998	999	.	.	.	O

O	1000	1008	Moreover	Moreover	RB	B-ADVP
O	1008	1009	,	,	,	O
O	1010	1018	computed	compute	VBN	B-NP
O	1019	1029	tomography	tomography	NN	I-NP
O	1030	1031	(	(	(	O
O	1031	1033	CT	CT	NN	B-NP
O	1033	1034	)	)	)	O
O	1035	1041	showed	show	VBD	B-VP
O	1042	1043	a	a	DT	B-NP
O	1044	1052	complete	complete	JJ	I-NP
O	1053	1063	regression	regression	NN	I-NP
O	1064	1066	of	of	IN	B-PP
O	1067	1070	the	the	DT	B-NP
O	1071	1080	extensive	extensive	JJ	I-NP
B-Cancer	1081	1086	lymph	lymph	NN	I-NP
I-Cancer	1087	1091	node	node	NN	I-NP
O	1092	1095	and	and	CC	O
O	1096	1103	diffuse	diffuse	JJ	B-NP
B-Cancer	1104	1108	lung	lung	NN	I-NP
I-Cancer	1109	1119	metastases	metastasis	NNS	I-NP
O	1119	1120	,	,	,	O
O	1121	1124	for	for	IN	B-PP
O	1125	1126	a	a	DT	B-NP
O	1127	1135	complete	complete	JJ	I-NP
O	1136	1144	response	response	NN	I-NP
O	1145	1146	(	(	(	O
O	1146	1148	CR	CR	NN	B-NP
O	1148	1149	)	)	)	O
O	1149	1150	.	.	.	O

O	1151	1154	The	The	DT	B-NP
B-Organism_substance	1155	1160	serum	serum	NN	I-NP
O	1161	1166	level	level	NN	I-NP
O	1167	1169	of	of	IN	B-PP
O	1170	1173	CEA	CEA	NN	B-NP
O	1174	1177	was	be	VBD	B-VP
O	1178	1185	reduced	reduce	VBN	I-VP
O	1186	1190	from	from	IN	B-PP
O	1191	1194	172	172	CD	B-NP
O	1194	1195	.	.	.	O
O	1195	1196	7	7	CD	B-NP
O	1197	1199	ng	ng	NN	I-NP
O	1199	1200	/	/	SYM	B-NP
O	1200	1202	ml	ml	NN	I-NP
O	1203	1205	to	to	TO	B-PP
O	1206	1207	8	8	CD	B-NP
O	1207	1208	.	.	.	O
O	1208	1209	1	1	CD	B-NP
O	1210	1212	ng	ng	NN	I-NP
O	1212	1213	/	/	SYM	B-NP
O	1213	1215	ml	ml	NN	I-NP
O	1216	1221	after	after	IN	B-PP
O	1222	1224	TS	TS	NN	B-NP
O	1224	1225	-	-	HYPH	B-NP
O	1225	1226	1	1	CD	I-NP
O	1227	1236	treatment	treatment	NN	I-NP
O	1236	1237	.	.	.	O

O	1238	1240	As	As	IN	B-PP
O	1241	1244	for	for	IN	B-PP
O	1245	1252	adverse	adverse	JJ	B-NP
O	1253	1259	events	event	NNS	I-NP
O	1259	1260	,	,	,	O
O	1261	1265	only	only	RB	B-NP
O	1266	1278	pigmentation	pigmentation	NN	I-NP
O	1279	1281	of	of	IN	B-PP
O	1282	1285	the	the	DT	B-NP
B-Organ	1286	1290	skin	skin	NN	I-NP
O	1291	1294	and	and	CC	I-NP
O	1295	1300	Grade	Grade	NN	I-NP
O	1301	1302	2	2	CD	I-NP
B-Pathological_formation	1303	1307	oral	oral	JJ	I-NP
I-Pathological_formation	1308	1313	aphta	aphta	NN	I-NP
O	1314	1318	were	be	VBD	B-VP
O	1319	1327	observed	observe	VBN	I-VP
O	1327	1328	.	.	.	O

